Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22848872 | 0.86 | KDM4E (0.39) | KDM4EEPHX1EPHX2DRD2CYP1A2 | |
| SCHEMBL23568926 | 0.84 | CARM1 (0.36) | KDM4EEPHX1EPHX2SIGMAR1 | |
| SCHEMBL24848351 | 0.84 | PRMT6 (0.35) | KDM4EEPHX1EPHX2 | |
| SCHEMBL23568498 | 0.84 | KDM4E (0.34) | KDM4E | |
| SCHEMBL24608220 | 0.84 | KDM4E (0.34) | KDM4ECYP2D6 | |
| SCHEMBL15113492 | 0.84 | NCF1 (0.31) | — | |
| SCHEMBL22848539 | 0.81 | KDM4E (0.32) | KDM4EEPHX1EPHX2CYP2D6 | |
| SCHEMBL25089661 | 0.81 | KDM4E (0.32) | KDM4E | |
| SCHEMBL25469075 | 0.80 | CYP2D6 (0.46) | CYP1A2CYP2D6 | |
| SCHEMBL26228251 | 0.80 | L3MBTL1 (0.37) | KDM4EEPHX1EPHX2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885EPHX1 1684/4885EPHX2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.